PD
SUPN icon

Point72 (DIFC)’s Supernus Pharmaceuticals SUPN Stock Holding History

Point72 (DIFC)’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-934
Closed -$29.4K – 1825
2025
Q2 		$29.4K Sell
934
-2,140
-70% -$68.6K ﹤0.01% 1174
2025
Q1 		$101K Buy
+3,074
New +$109K ﹤0.01% 1068
2024
Q4 		– Sell
-455
Closed -$14.2K – 1890
2024
Q3 		$14.2K Buy
+455
New +$14.2K ﹤0.01% 1235
2024
Q2 		– Sell
-4,201
Closed -$143K – 1885
2024
Q1 		$143K Buy
+4,201
New +$125K ﹤0.01% 1029

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 (DIFC)'s SUPN Position: Q3 2025 in Review

Point72 (DIFC) sold out of Supernus Pharmaceuticals (SUPN) in Q3 2025, closing a stake of 934 shares — an estimated $29.4K sold.

Point72 (DIFC) first reported a position in SUPN in Q1 2024 and held it in 4 quarters. The position peaked at $143K in Q1 2024. 310 funds tracked by Wall St. Rank hold SUPN as of Q3 2025.

  • Point72 (DIFC) reported no remaining Supernus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Point72 (DIFC) sold 934 Supernus Pharmaceuticals shares in Q3 2025, an estimated $29.4K.
  • Point72 (DIFC) first reported a position in Supernus Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Point72 (DIFC)'s Supernus Pharmaceuticals position peaked at $143K in Q1 2024.
  • 310 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.